Needham Maintains Buy on Azenta, Lowers Price Target to $68
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $78 to $68.
Exagen Inc. Elects Tina S. Nova, Ph.D. As Executive Chair Of The Board Of Directors
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19,
What To Know About Evercore ISI Group’s Downgrade of Azenta
Evercore ISI Group downgraded its rating of Azenta (NASDAQ:AZTA) to In-Line with a price target of $62.00, changing…
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here is the list of some big stocks recording gains in the previous session.
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split.
Needham Maintains Buy on Azenta, Raises Price Target to $78
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and raises the price target from $74 to $78.
Nasdaq, S&P 500 Futures Skyrocket After Tamer PPI Data That Confirms Slowing Inflation, Walmart’s Beat-And-Raise Q3
The index futures are solidly higher in premarket trading on Tuesday, as stocks strive to return to winning ways amid lingering hopes of a Fed pause.
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Keybanc Maintains Overweight on Azenta, Lowers Price Target to $70
Keybanc analyst Paul Knight maintains Azenta (NASDAQ:AZTA) with a Overweight and lowers the price target from $90 to $70.